Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
Clinical trial NCT03068624 · UNKNOWN
Trial details
- NCT number
- NCT03068624
- Sponsor
- M.D. Anderson Cancer Center
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-08
- Primary completion
- 2022-12-31
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.